{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:17:05Z","timestamp":1767849425561,"version":"3.49.0"},"reference-count":17,"publisher":"American Society for Microbiology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>A new vaccine (the 4CMenB 4-component protein vaccine [Bexsero], which includes PorA, factor H-binding protein [fHbp], neisserial heparin-binding antigen [NHBA], and<jats:named-content content-type=\"genus-species\">Neisseria<\/jats:named-content>adhesin A [NadA]) against serogroup B meningococci has recently been approved for use in people older than age 2 months in Europe, Australia, and Canada. Preapproval clinical efficacy studies are not feasible for invasive meningococcal disease because its incidence is low\/very low, and the serum bactericidal antibody (SBA) titer (or the human SBA [hSBA] titer when human complement is used in the assay) has been used as a surrogate marker of protection. However, the hSBA assay cannot be used on a large scale, and therefore, a meningococcal antigen typing system (MATS) was developed. MATS combines conventional PorA genotyping with an enzyme-linked immunosorbent assay (ELISA) that quantifies both the expression and the cross-reactivity of antigenic variants. The assay has been used to evaluate the potential of the 4CMenB meningococcal group B vaccine to cover group B strains in several countries. Some recent data suggest that MATS is a conservative predictor of strain coverage. We used pooled sera from adolescents and infants to test by the hSBA assay 10 meningococcal group B strains isolated in Spain that were negative for the 3 antigens (<jats:italic>n<\/jats:italic>= 9) or that had very low levels of the 3 antigens (<jats:italic>n<\/jats:italic>= 1) by MATS. We found that all strains were killed by sera from adolescents and that 5 of the 10 strains were also killed, although at a low titer, by sera from infants. Our data confirm that MATS underestimates vaccine coverage.<\/jats:p>","DOI":"10.1128\/cvi.00669-14","type":"journal-article","created":{"date-parts":[[2015,1,29]],"date-time":"2015-01-29T02:37:03Z","timestamp":1422499023000},"page":"357-360","source":"Crossref","is-referenced-by-count":26,"title":["A Large Portion of Meningococcal Antigen Typing System-Negative Meningococcal Strains from Spain Is Killed by Sera from Adolescents and Infants Immunized with 4CMenB"],"prefix":"10.1128","volume":"22","author":[{"given":"R.","family":"Abad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Biolchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Moschioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2015,1,28]]},"reference":[{"key":"key20180919073759_B1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the development of vaccines against Neisseria meningitidis","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180919073759_B2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/3527608508.ch16","article-title":"Subrogates of protection","volume-title":"Handbook of meningococcal disease","year":"2006"},{"key":"key20180919073759_B3","doi-asserted-by":"publisher","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20180919073759_B4","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1128\/CVI.00202-12","article-title":"Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines","volume":"19","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"key20180919073759_B5","doi-asserted-by":"publisher","first-page":"B73","DOI":"10.1016\/j.vaccine.2011.12.061","article-title":"The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073759_B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40265-013-0155-7","article-title":"A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program","volume":"74","year":"2014","journal-title":"Drugs"},{"key":"key20180919073759_B7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"key20180919073759_B8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"members of the Canadian Immunization Monitoring Program, Active (IMPACT)","year":"2013","journal-title":"Vaccine"},{"key":"key20180919073759_B9","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","year":"2013","journal-title":"Vaccine"},{"key":"key20180919073759_B10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"V72P10 Meningococcal B Adolescent Vaccine Study Group","year":"2012","journal-title":"Lancet"},{"key":"key20180919073759_B11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"European MenB Vaccine Study Group","year":"2012","journal-title":"JAMA"},{"key":"key20180919073759_B12","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","year":"1969","journal-title":"J Exp Med"},{"key":"key20180919073759_B13","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1128\/IAI.67.5.2441-2451.1999","article-title":"Humoral immune responses to Neisseria meningitidis in children","volume":"67","year":"1999","journal-title":"Infect Immun"},{"key":"key20180919073759_B14","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1016\/j.vaccine.2010.12.075","article-title":"Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen","volume":"29","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073759_B15","article-title":"Pooled hSBA titers predict seroresponse rates of infants vaccinated with 4CMenB","year":"2014"},{"key":"key20180919073759_B16","doi-asserted-by":"publisher","first-page":"B64","DOI":"10.1016\/j.vaccine.2009.04.061","article-title":"Meningococcal carriage and disease\u2014population biology and evolution","volume":"27","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073759_B17","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1128\/CVI.00341-07","article-title":"Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody","volume":"14","year":"2007","journal-title":"Clin Vaccine Immunol"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00669-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:51:28Z","timestamp":1627591888000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00669-14"}},"subtitle":[],"editor":[{"given":"S. A.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,1,28]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,3,26]]},"published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1128\/CVI.00669-14"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00669-14","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,28]]}}}